Skip to content

Amarantus Bioscience Holdings, Inc.: 10-Q filed 2013-08-19

What Amarantus Bioscience Holdings, Inc. reported in its quarterly report filed 2013-08-19 (fiscal Q2 2013): 24 published measures, 69 facts as tagged in accession 0001255294-13-000667.

This filing

Form
10-Q (quarterly report)
Filed
2013-08-19
Fiscal period
fiscal Q2 2013
Accession
0001255294-13-000667 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Amarantus Bioscience Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-06-301,127,181USD
At 2012-12-311,209,937USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-06-305,576,483USD
At 2012-12-314,737,753USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-06-30-4,449,302USD
At 2012-12-31-3,527,816USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-06-3067,071USD
At 2012-12-31157,174USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-3,758,173USD181
2008-01-14 to 2013-06-30-15,254,351USD1995
2012-01-01 to 2012-06-30-2,312,658USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-1,646,403USD181
2008-01-14 to 2013-06-30-6,379,422USD1995
2012-01-01 to 2012-06-30-267,070USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2008-01-14 to 2013-06-30-40,392USD1995

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-06-301,590,300USD181
2008-01-14 to 2013-06-306,576,885USD1995
2012-01-01 to 2012-06-30272,848USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-34,000USD181
2008-01-14 to 2013-06-30-130,392USD1995

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2013-04-01 to 2013-06-30397,175,440shares91
2013-01-01 to 2013-06-30380,084,393shares181
2012-04-01 to 2012-06-30101,415,191shares91
2012-01-01 to 2012-06-3094,635,577shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2013-04-01 to 2013-06-300USD/shares91
2013-01-01 to 2013-06-30-0.01USD/shares181
2012-04-01 to 2012-06-30-0.01USD/shares91
2012-01-01 to 2012-06-30-0.02USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-06-30597,582USD181
2008-01-14 to 2013-06-301,662,613USD1995
2012-01-01 to 2012-06-301,400,760USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-900,885USD91
2013-01-01 to 2013-06-30-3,758,173USD181
2008-01-14 to 2013-06-30-15,254,351USD1995
2012-04-01 to 2012-06-30-995,327USD91
2012-01-01 to 2012-06-30-2,312,658USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-06-30481,038USD
At 2012-12-31676,794USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-06-305,576,483USD
At 2012-12-314,737,753USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-06-302,617,006USD
At 2012-12-312,596,848USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-04-01 to 2013-06-30474,671USD91
2013-01-01 to 2013-06-301,138,596USD181
2008-01-14 to 2013-06-303,157,710USD1995
2012-04-01 to 2012-06-30359,829USD91
2012-01-01 to 2012-06-30435,745USD182

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-06-3010,728,916USD
At 2012-12-317,991,465USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-06-30413,967USD
At 2012-12-31519,620USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2013-04-01 to 2013-06-30-1,304,475USD91
2013-01-01 to 2013-06-30-3,189,072USD181
2008-01-14 to 2013-06-30-12,913,651USD1995
2012-04-01 to 2012-06-30-934,682USD91
2012-01-01 to 2012-06-30-2,300,447USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-30829,804USD91
2013-01-01 to 2013-06-302,050,476USD181
2008-01-14 to 2013-06-3010,171,937USD1995
2012-04-01 to 2012-06-30574,853USD91
2012-01-01 to 2012-06-301,864,702USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2008-01-14 to 2013-06-3033,014USD1995
2012-04-01 to 2012-06-302,904USD91
2012-01-01 to 2012-06-305,809USD182
2008-01-14 to 2012-06-3031,562USD1630

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2008-01-14 to 2013-06-301,797,941USD1995

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-06-30954,126USD181
2008-01-14 to 2013-06-304,344,784USD1995
2012-01-01 to 2012-06-30720,128USD182

Inspect the source

Entity
Amarantus Bioscience Holdings, Inc. / CIK 0001424812
Captured
SEC response SHA-256
ea2483eca01d115e34db075669ce2910547b639494a749eaab5130b08e1b48ca

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001424812.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))